693 related articles for article (PubMed ID: 9034987)
1. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
2. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
4. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
Muzaffer MA; Dayer JM; Feldman BM; Pruzanski W; Roux-Lombard P; Schneider R; Laxer RM; Silverman ED
J Rheumatol; 2002 May; 29(5):1071-8. PubMed ID: 12022325
[TBL] [Abstract][Full Text] [Related]
5. Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schönlein purpura and pediatric systemic lupus erythematosus: pathogenetic implications.
Gattorno M; Picco P; Barbano G; Stalla F; Sormani MP; Buoncompagni A; Gusmano R; Borrone C; Pistoia V
J Rheumatol; 1998 Feb; 25(2):361-5. PubMed ID: 9489835
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
[TBL] [Abstract][Full Text] [Related]
9. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
[TBL] [Abstract][Full Text] [Related]
10. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
12. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
13. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.
Descamps-Latscha B; Herbelin A; Nguyen AT; Roux-Lombard P; Zingraff J; Moynot A; Verger C; Dahmane D; de Groote D; Jungers P
J Immunol; 1995 Jan; 154(2):882-92. PubMed ID: 7814891
[TBL] [Abstract][Full Text] [Related]
14. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
[TBL] [Abstract][Full Text] [Related]
15. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.
Ida H; Kawasaki E; Miyashita T; Tanaka F; Kamachi M; Izumi Y; Huang M; Tamai M; Origuchi T; Kawakami A; Migita K; Motomura M; Yoshimura T; Eguchi K
Rheumatology (Oxford); 2004 Oct; 43(10):1292-9. PubMed ID: 15280569
[TBL] [Abstract][Full Text] [Related]
16. Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease.
Bakri Hassan A; Rönnelid J; Gunnarsson I; Karlsson G; Berg L; Lundberg I
J Autoimmun; 1998 Oct; 11(5):503-8. PubMed ID: 9802936
[TBL] [Abstract][Full Text] [Related]
17. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
18. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer.
Barber MD; Fearon KC; Ross JA
Clin Sci (Lond); 1999 Jan; 96(1):83-7. PubMed ID: 9857110
[TBL] [Abstract][Full Text] [Related]
19. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis.
Gabay C; Roux-Lombard P; de Moerloose P; Dayer JM; Vischer T; Guerne PA
J Rheumatol; 1993 May; 20(5):815-21. PubMed ID: 8336307
[TBL] [Abstract][Full Text] [Related]
20. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
